CA-GLOBALLOGIC
5.5.2021 14:32:06 CEST | Business Wire | Press release
GlobalLogic Inc. , a leader in Digital Product Engineering, today announced it has earned the Kubernetes on Microsoft Azure advanced specialization, a validation of a solution partner’s deep knowledge, extensive experience and proven expertise in deploying and managing production workloads in the cloud using containers and managing hosted Kubernetes environments in Microsoft Azure. GlobalLogic pursued this particular capability to keep in step with its customers’ growing need for a robust, scalable container orchestration system capable of supporting their digital transformation journeys.
Only partners that meet stringent criteria around customer success and staff skilling, as well as pass a third-party audit of their container-based workload deployment and management practices, are able to earn the Kubernetes on Azure advanced specialization.
With over 75% of global organizations expected to run containerized applications in production by 2022, many are looking for a partner with advanced skills to migrate their existing containerized workloads to the cloud or assist them in developing cloud-native applications using container technologies, DevOps patterns, and a microservices approach.
Kubernetes is a portable, extensible, open-source platform for managing containerized workloads and services across virtual machines. It facilitates both declarative configuration and automation while optimizing required compute power. Collectively, these features are known to simplify cloud migration, shorten software development cycles, and reduce cloud costs among other benefits.
Overseen by the Cloud Native Computing Foundation (CNCF), Kubernetes is growing rapidly in popularity. In March 2020, the organization released its 2019 survey results assessing cloud native adoption trends according to more than 1300 respondents. Container use itself in 2019 increased to 84 percent—a 15 percent jump from 2018. Importantly, 78 percent of respondents are using Kubernetes in production.
“Sophisticated container orchestration is a necessary function to modern, digital business models—particularly as a computing tool that we can smartly pair with microservice architectures for stronger platform optimization,” said Raja Renganathan, SVP and GM, Cloud Engineering, GlobalLogic. “The clear benefits of Kubernetes in a Microsoft Azure environment is increasingly important as we help global brands quickly design, develop and bring to market engaging new products and services that promise new revenue streams.”
Rodney Clark, Corporate Vice President, Global Partner Solutions, Channel Sales and Channel Chief at Microsoft, added, “The Kubernetes on Microsoft Azure advanced specialization highlights the partners who can be viewed as most capable when it comes to deploying and managing containerized applications in Azure. GlobalLogic clearly demonstrated that they have both the skills and the experience to deliver best-in-class cloud-native capabilities to customers with Azure.
Useful Links
GlobalLogic: http://www.globallogic.com
LinkedIn: https://www.linkedin.com/company/globallogic/
Facebook: https://www.facebook.com/GlobalLogic/
Twitter: https://twitter.com/GlobalLogic
About GlobalLogic
GlobalLogic (www.globallogic.com ) is a leader in digital product engineering. We help our clients design and build innovative products, platforms, and digital experiences for the modern world. By integrating strategic design, complex engineering, and vertical industry expertise—we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the communications, financial services, automotive, healthcare, technology, media and entertainment, manufacturing, and semiconductor industries.
GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210505005148/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom